ALLIGATOR BIOSCIENCE AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.78 SEK | +0.39% |
|
-7.69% | +13.21% |
| 05-06 | Transcript : Alligator Bioscience AB, Q1 2024 Earnings Call, May 06, 2024 | |
| 05-06 | Alligator Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 753.9 | 567.5 | 566.9 | 341.9 | 453.3 | 589 | - | - |
| Enterprise Value (EV) 1 | 574 | 476.3 | 298.5 | 269.1 | 403.3 | 194.5 | 589 | 589 |
| P/E ratio | -3.59 x | -3.96 x | -4.02 x | -1.76 x | -1.25 x | -1.71 x | -7.75 x | -19.4 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 140 x | 85.1 x | 37.5 x | 9.21 x | 7.32 x | 2.26 x | 4.81 x | 4.75 x |
| EV / Revenue | 106 x | 71.4 x | 19.7 x | 7.25 x | 6.52 x | 0.74 x | 4.81 x | 4.75 x |
| EV / EBITDA | -2.83 x | -3.59 x | -2.29 x | -1.49 x | -1.69 x | 32.6 x | -7.03 x | -9.36 x |
| EV / FCF | -3.17 x | -3.37 x | -2.35 x | -1.56 x | -2.1 x | -0.97 x | -3.01 x | -8.92 x |
| FCF Yield | -31.6% | -29.7% | -42.6% | -64.3% | -47.5% | -103% | -33.3% | -11.2% |
| Price to Book | 2.92 x | 4.92 x | 2.01 x | 3.88 x | 34.5 x | 1.65 x | - | - |
| Nbr of stocks (in thousands) | 71,389 | 71,389 | 220,585 | 220,585 | 657,954 | 758,039 | - | - |
| Reference price 2 | 10.56 | 7.950 | 2.570 | 1.550 | 0.6890 | 0.7770 | 0.7770 | 0.7770 |
| Announcement Date | 20-02-12 | 21-02-26 | 22-02-11 | 23-02-10 | 24-02-08 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 5.396 | 6.666 | 15.13 | 37.14 | 61.9 | 261.2 | 122.4 | 123.9 |
| EBITDA 1 | -203 | -132.8 | -130.4 | -181 | -238.5 | 5.963 | -83.72 | -62.9 |
| EBIT 1 | -214.5 | -144.3 | -141.6 | -192.8 | -249 | -2.287 | -90.22 | -69.4 |
| Operating Margin | -3,975.17% | -2,164.69% | -936.14% | -519.16% | -402.22% | -0.88% | -73.73% | -56.01% |
| Earnings before Tax (EBT) 1 | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -6.113 | -89.72 | -68.9 |
| Net income 1 | -210.1 | -143.3 | -141.7 | -193.4 | -248.6 | -6.113 | -89.72 | -68.9 |
| Net margin | -3,893.85% | -2,149.65% | -936.8% | -520.81% | -401.58% | -2.34% | -73.32% | -55.61% |
| EPS 2 | -2.940 | -2.010 | -0.6400 | -0.8800 | -0.5500 | -0.4553 | -0.1003 | -0.0400 |
| Free Cash Flow 1 | -181.1 | -141.5 | -127.1 | -173 | -191.7 | -201 | -196 | -66 |
| FCF margin | -3,357.08% | -2,122.02% | -840.13% | -465.99% | -309.76% | -76.96% | -160.16% | -53.27% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 20-02-12 | 21-02-26 | 22-02-11 | 23-02-10 | 24-02-08 | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 180 | 91.3 | 268 | 72.8 | 50 | 395 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -181 | -141 | -127 | -173 | -192 | -201 | -196 | -66 |
| ROE (net income / shareholders' equity) | -57.8% | -76.7% | -71.3% | -104% | -493% | -88.1% | -1,417% | - |
| ROA (Net income/ Total Assets) | -51.3% | -61.9% | -58.4% | -76.9% | -173% | -193% | -169% | -74.9% |
| Assets 1 | 409.6 | 231.5 | 242.5 | 251.4 | 144 | 3.163 | 53.12 | 91.99 |
| Book Value Per Share 2 | 3.620 | 1.610 | 1.280 | 0.4000 | 0.0200 | 0.4700 | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 2.07 | 0.1 | 0.05 | 0.44 | 2.46 | 0.03 | - | - |
| Capex / Sales | 38.34% | 1.53% | 0.3% | 1.18% | 3.97% | 0.01% | - | - |
| Announcement Date | 20-02-12 | 21-02-26 | 22-02-11 | 23-02-10 | 24-02-08 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.777
SEK
Average target price
1.9
SEK
Spread / Average Target
+144.53%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +13.21% | 54.35M | |
| +26.74% | 44.96B | |
| +0.24% | 42.65B | |
| +46.00% | 41.85B | |
| -5.31% | 29.04B | |
| +10.22% | 26.08B | |
| -21.20% | 19.03B | |
| +6.67% | 12.75B | |
| +28.79% | 12.06B | |
| -3.93% | 11.75B |
- Stock Market
- Equities
- ATORX Stock
- Financials Alligator Bioscience AB